2.1 Study participants and sample collection
Participants were recruited as part of a pilot for the ACCENT (A C anadian study of C isplatin mE tabolomics and N ephroT oxicity) study, an ongoing Canada-wide, multi-center initiative to identify serum and urine metabolites for the prediction or early diagnosis of cisplatin-induced nephrotoxicity. The ACCENT study is being conducted in accordance with the Medical Association Declaration of Helsinki. After receiving written informed consent, 31 adult patients were recruited at the London Regional Cancer Program (Victoria Hospital, London, ON, Canada) between 2018-2020. Ethics approval for this study was obtained from the Health Sciences Research Ethics Board at the University of Western Ontario. The cohort included adult patients (>18 years of age) initiating cisplatin treatment (dose ≥ 70 mg m2 -1) for head and neck cancer. Exclusion criteria were chronic kidney disease (GFR < 60 ml min-1) at baseline, previous exposure to cisplatin/other nephrotoxic drugs in the 2 weeks leading up to cisplatin treatment, radiotherapy within 1 month prior to the study, or previous hematopoietic stem cell transplant. Patient demographic information (Table 1 ) was recorded upon enrollment. Urine and blood samples were collected from patients prior to (“pre”), 24–48 hours after (“24-48h”), and 5-14 days following (“post”) each cisplatin infusion, and laboratory results/patient data were collected for each sample collection timepoint. Samples were stored at -80°C prior to analysis. A detailed outline of the ACCENT study has been previously published.